WO2005087749A1 - 2−アミノキナゾリン誘導体 - Google Patents
2−アミノキナゾリン誘導体 Download PDFInfo
- Publication number
- WO2005087749A1 WO2005087749A1 PCT/JP2005/004565 JP2005004565W WO2005087749A1 WO 2005087749 A1 WO2005087749 A1 WO 2005087749A1 JP 2005004565 W JP2005004565 W JP 2005004565W WO 2005087749 A1 WO2005087749 A1 WO 2005087749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- compound
- unsubstituted
- acceptable salt
- aminoquinazoline derivative
- Prior art date
Links
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title claims description 69
- 150000003839 salts Chemical class 0.000 claims abstract description 93
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 48
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 34
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- -1 hydroxy, carboxy Chemical group 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 27
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- JRGBSVQGSBEEEU-UHFFFAOYSA-N 2-aminoquinazoline-4-carboxylic acid Chemical group C1=CC=CC2=NC(N)=NC(C(O)=O)=C21 JRGBSVQGSBEEEU-UHFFFAOYSA-N 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 8
- 125000003107 substituted aryl group Chemical group 0.000 abstract description 6
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 286
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 90
- 239000002904 solvent Substances 0.000 description 81
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- 239000000203 mixture Substances 0.000 description 58
- 238000005160 1H NMR spectroscopy Methods 0.000 description 51
- 239000011541 reaction mixture Substances 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 43
- 230000002829 reductive effect Effects 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 38
- 239000013078 crystal Substances 0.000 description 37
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 230000008569 process Effects 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
- 239000002585 base Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 19
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 229910052763 palladium Inorganic materials 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 238000009835 boiling Methods 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- MHVHVXWBYRZGRQ-UHFFFAOYSA-N 5-bromo-8-methoxy-n-methylquinazolin-2-amine Chemical compound BrC1=CC=C(OC)C2=NC(NC)=NC=C21 MHVHVXWBYRZGRQ-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 7
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000004434 sulfur atom Chemical group 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 238000001665 trituration Methods 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000013065 commercial product Substances 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 5
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 4
- OQDUONHFGRRMGY-UHFFFAOYSA-N 2-bromo-4-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=C(Br)C=C1F OQDUONHFGRRMGY-UHFFFAOYSA-N 0.000 description 4
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 4
- SDCPFJIHUUMVDR-UHFFFAOYSA-N 4-boronooxybenzoic acid Chemical compound OB(O)OC1=CC=C(C(O)=O)C=C1 SDCPFJIHUUMVDR-UHFFFAOYSA-N 0.000 description 4
- CADROLUKPPVPJY-UHFFFAOYSA-N 5-cyclohexyl-8-methoxy-n-methylquinazolin-2-amine Chemical compound C=1C=C(OC)C2=NC(NC)=NC=C2C=1C1CCCCC1 CADROLUKPPVPJY-UHFFFAOYSA-N 0.000 description 4
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 4
- XQCFATPSDSZGQU-WKILWMFISA-N COC=1C2=NC(NC)=NC=C2C(C=2C=CC=CC=2)=CC=1[C@H]1CC[C@H](O)CC1 Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=CC=CC=2)=CC=1[C@H]1CC[C@H](O)CC1 XQCFATPSDSZGQU-WKILWMFISA-N 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940126208 compound 22 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- QJJUEZGJAGUHDT-UKTHLTGXSA-N ethyl (e)-3-[5-(3-chlorophenyl)-8-methoxy-2-(methylamino)quinazolin-7-yl]-2-methylprop-2-enoate Chemical compound C=12C=NC(NC)=NC2=C(OC)C(/C=C(\C)C(=O)OCC)=CC=1C1=CC=CC(Cl)=C1 QJJUEZGJAGUHDT-UKTHLTGXSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- HFYSPQWJTHOLID-UHFFFAOYSA-N 2-[4-[5-(3-chlorophenyl)-8-methoxy-2-(methylamino)quinazolin-7-yl]phenoxy]acetic acid Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=CC=2)=CC=1C1=CC=C(OCC(O)=O)C=C1 HFYSPQWJTHOLID-UHFFFAOYSA-N 0.000 description 3
- UYMDHUMVFDCTDB-UHFFFAOYSA-N 2-[4-[5-(5-chloropyridin-3-yl)-8-methoxy-2-(methylamino)quinazolin-7-yl]phenyl]-2-methylpropanoic acid Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=NC=2)=CC=1C1=CC=C(C(C)(C)C(O)=O)C=C1 UYMDHUMVFDCTDB-UHFFFAOYSA-N 0.000 description 3
- HSLMSLWCQUZYNJ-UHFFFAOYSA-N 2-[4-[5-(5-chloropyridin-3-yl)-8-methoxy-2-(methylamino)quinazolin-7-yl]phenyl]acetic acid Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=NC=2)=CC=1C1=CC=C(CC(O)=O)C=C1 HSLMSLWCQUZYNJ-UHFFFAOYSA-N 0.000 description 3
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 3
- VPUASHSVUSEHTH-UHFFFAOYSA-N 4-(2-bromo-4-fluoro-3-formyl-5-methoxyphenyl)benzoic acid Chemical compound O=CC1=C(F)C(OC)=CC(C=2C=CC(=CC=2)C(O)=O)=C1Br VPUASHSVUSEHTH-UHFFFAOYSA-N 0.000 description 3
- LUOWDJHJCSCVKS-UHFFFAOYSA-N 5-(3,6-dihydro-2h-pyran-4-yl)-8-methoxy-n-methylquinazolin-2-amine Chemical compound C=1C=C(OC)C2=NC(NC)=NC=C2C=1C1=CCOCC1 LUOWDJHJCSCVKS-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 101100020289 Xenopus laevis koza gene Proteins 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000010531 catalytic reduction reaction Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940127113 compound 57 Drugs 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- OHDHPJDCSNRECG-UHFFFAOYSA-N (2,3-ditert-butylphenyl)-phenylphosphane Chemical compound C(C)(C)(C)C=1C(=C(C=CC=1)PC1=CC=CC=C1)C(C)(C)C OHDHPJDCSNRECG-UHFFFAOYSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 2
- IVUXRZHILJVPSJ-UHFFFAOYSA-N 2-(5-bromofuran-2-yl)acetic acid Chemical compound OC(=O)CC1=CC=C(Br)O1 IVUXRZHILJVPSJ-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 2
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 2
- OAUATVLSXKAENX-UHFFFAOYSA-N 8-methoxy-n-methyl-5-piperidin-1-ylquinazolin-2-amine Chemical compound C=1C=C(OC)C2=NC(NC)=NC=C2C=1N1CCCCC1 OAUATVLSXKAENX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- AUNPJTATRUUHDZ-UHFFFAOYSA-N ethyl 2-(5-bromofuran-2-yl)acetate Chemical compound CCOC(=O)CC1=CC=C(Br)O1 AUNPJTATRUUHDZ-UHFFFAOYSA-N 0.000 description 2
- WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- PKAUVIXBZJUYRV-UHFFFAOYSA-N methane;hydroiodide Chemical compound C.I PKAUVIXBZJUYRV-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- LDYSWDMNYLEUCU-CCXLZGIPSA-N (1S,2S,4S,6R,7S,10R,11R)-6-hydroxy-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.24,7.01,10.02,7]nonadecan-8-one Chemical compound C[C@]12CCC[C@]3(CN(CCO)C1)[C@@H]2CC(=O)[C@@]12CC[C@@H](C[C@@H]31)C(=C)[C@H]2O LDYSWDMNYLEUCU-CCXLZGIPSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- NOLMGELTBIIGOL-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate Chemical compound C1CC(OS(=O)(=O)C(F)(F)F)=CCC21OCCO2 NOLMGELTBIIGOL-UHFFFAOYSA-N 0.000 description 1
- BHTZCIGVYSJBQB-UHFFFAOYSA-N 1-(1h-pyrazol-5-yl)ethanone Chemical compound CC(=O)C=1C=CNN=1 BHTZCIGVYSJBQB-UHFFFAOYSA-N 0.000 description 1
- FISAFHRJFUCPOC-UHFFFAOYSA-N 1-bromo-2-(dimethoxymethyl)-5-fluoro-4-methoxybenzene Chemical compound COC(OC)C1=CC(OC)=C(F)C=C1Br FISAFHRJFUCPOC-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
- NFGJQVPDPIGBJE-UHFFFAOYSA-N 2-(4-boronophenyl)acetic acid Chemical compound OB(O)C1=CC=C(CC(O)=O)C=C1 NFGJQVPDPIGBJE-UHFFFAOYSA-N 0.000 description 1
- NRDUHXQTTOHIJX-UHFFFAOYSA-N 2-(4-bromophenoxy)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Br)C=C1 NRDUHXQTTOHIJX-UHFFFAOYSA-N 0.000 description 1
- AKVOQXBQLXOEEF-UHFFFAOYSA-N 2-(4-bromophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=C(Br)C=C1 AKVOQXBQLXOEEF-UHFFFAOYSA-N 0.000 description 1
- XJLITJHUQRBWPN-UHFFFAOYSA-N 2-acetamidoacetic acid;4-[2-(4-carbamimidoylphenyl)iminohydrazinyl]benzenecarboximidamide Chemical compound CC(=O)NCC(O)=O.C1=CC(C(=N)N)=CC=C1NN=NC1=CC=C(C(N)=N)C=C1 XJLITJHUQRBWPN-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- PFMLXBKZXKKKBK-UHFFFAOYSA-N 2-bromo-3-(dimethoxymethyl)-6-fluoro-5-methoxybenzaldehyde Chemical compound COC(OC)C1=CC(OC)=C(F)C(C=O)=C1Br PFMLXBKZXKKKBK-UHFFFAOYSA-N 0.000 description 1
- NAAFSIVWSAKSRZ-UHFFFAOYSA-N 2-hydroxyethyl 2-aminoethanesulfonate Chemical compound NCCS(=O)(=O)OCCO NAAFSIVWSAKSRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FBHLBPYGCOBDRK-UHFFFAOYSA-N 3-[4-(trifluoromethylsulfonyloxy)phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 FBHLBPYGCOBDRK-UHFFFAOYSA-N 0.000 description 1
- UHHRBENVOAYPNE-UHFFFAOYSA-N 3-[4-[5-(3-chlorophenyl)-8-methoxy-2-(methylamino)quinazolin-7-yl]phenyl]propanoic acid Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=CC=2)=CC=1C1=CC=C(CCC(O)=O)C=C1 UHHRBENVOAYPNE-UHFFFAOYSA-N 0.000 description 1
- VLSWVHQAZQWVAK-UHFFFAOYSA-N 3-[8-methoxy-2-(methylamino)-5-phenylquinazolin-7-yl]-2-methylpropanoic acid Chemical compound C=1C(CC(C)C(O)=O)=C(OC)C2=NC(NC)=NC=C2C=1C1=CC=CC=C1 VLSWVHQAZQWVAK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGNLHMKIGMZKJX-UHFFFAOYSA-N 3-chloro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(Cl)=C1 QGNLHMKIGMZKJX-UHFFFAOYSA-N 0.000 description 1
- WCKBNAJTZUVHPD-UHFFFAOYSA-N 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=CC(Cl)=C1 WCKBNAJTZUVHPD-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- TWBAXVJGVNVEJH-UHFFFAOYSA-N 3-methylpyridazine;hydrochloride Chemical compound Cl.CC1=CC=CN=N1 TWBAXVJGVNVEJH-UHFFFAOYSA-N 0.000 description 1
- YIDSVQQXKMNEHE-UHFFFAOYSA-N 4-(2-amino-5-bromo-8-methoxyquinazolin-6-yl)benzoic acid Chemical compound BrC=1C2=CN=C(N)N=C2C(OC)=CC=1C1=CC=C(C(O)=O)C=C1 YIDSVQQXKMNEHE-UHFFFAOYSA-N 0.000 description 1
- QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 1
- CGVULGISIYSCNS-UHFFFAOYSA-N 4-[5-(3-chlorophenyl)-8-(difluoromethoxy)-2-(methylamino)quinazolin-7-yl]benzoic acid Chemical compound FC(F)OC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=CC=2)=CC=1C1=CC=C(C(O)=O)C=C1 CGVULGISIYSCNS-UHFFFAOYSA-N 0.000 description 1
- GMDGJCJKWDLGFR-UHFFFAOYSA-N 4-[5-(5-chloropyridin-3-yl)-8-methoxy-2-(methylamino)quinazolin-6-yl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1C=1C=C(OC)C2=NC(NC)=NC=C2C=1C1=CN=CC(Cl)=C1 GMDGJCJKWDLGFR-UHFFFAOYSA-N 0.000 description 1
- XVBCOCUHCPXNPZ-UHFFFAOYSA-N 4-[8-methoxy-2-(methylamino)-5-phenyl-1,4-dihydroquinazolin-7-yl]cyclohexan-1-ol Chemical compound C1NC(NC)=NC(C=2OC)=C1C(C=1C=CC=CC=1)=CC=2C1CCC(O)CC1 XVBCOCUHCPXNPZ-UHFFFAOYSA-N 0.000 description 1
- SUVYXKDAVYFUMG-UHFFFAOYSA-N 4-aminobutan-2-one Chemical compound CC(=O)CCN SUVYXKDAVYFUMG-UHFFFAOYSA-N 0.000 description 1
- SEVMQEIGENUPIE-UHFFFAOYSA-N 4-bromo-1-fluoro-2-methoxybenzene Chemical compound COC1=CC(Br)=CC=C1F SEVMQEIGENUPIE-UHFFFAOYSA-N 0.000 description 1
- DJZAABLAECNINV-UHFFFAOYSA-N 4-bromo-2,6-dimethylbenzoic acid Chemical compound CC1=CC(Br)=CC(C)=C1C(O)=O DJZAABLAECNINV-UHFFFAOYSA-N 0.000 description 1
- RYVOZMPTISNBDB-UHFFFAOYSA-N 4-bromo-2-fluorophenol Chemical compound OC1=CC=C(Br)C=C1F RYVOZMPTISNBDB-UHFFFAOYSA-N 0.000 description 1
- PAJSESFUWIYFNF-UHFFFAOYSA-N 4-bromo-3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C(O)=C1 PAJSESFUWIYFNF-UHFFFAOYSA-N 0.000 description 1
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 1
- NALVGTOMKSKFFV-UHFFFAOYSA-N 4-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1F NALVGTOMKSKFFV-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- GIXOHFMAPZMBSA-UHFFFAOYSA-N 5-(3-chlorophenyl)-8-methoxy-n,n-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine Chemical compound C12=CN=C(N(C)C)N=C2C(OC)=C(B2OC(C)(C)C(C)(C)O2)C=C1C1=CC=CC(Cl)=C1 GIXOHFMAPZMBSA-UHFFFAOYSA-N 0.000 description 1
- UMLMSODQPJJANY-UHFFFAOYSA-N 5-(3-chlorophenyl)-8-methoxy-n-methylquinazolin-2-amine Chemical compound C=1C=C(OC)C2=NC(NC)=NC=C2C=1C1=CC=CC(Cl)=C1 UMLMSODQPJJANY-UHFFFAOYSA-N 0.000 description 1
- YMZMDMWMKVPGDP-UHFFFAOYSA-N 5-(4-bromophenyl)-2h-tetrazole Chemical compound C1=CC(Br)=CC=C1C1=NNN=N1 YMZMDMWMKVPGDP-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- CFGFKMRBXQJVMO-UHFFFAOYSA-N 5-(5-chloropyridin-3-yl)-8-methoxy-n-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=C(Cl)C=NC=2)=CC=1B1OC(C)(C)C(C)(C)O1 CFGFKMRBXQJVMO-UHFFFAOYSA-N 0.000 description 1
- QMRQWRNTAHSJMH-UHFFFAOYSA-N 5-bromo-6-(dimethoxymethyl)-8-methoxy-n-methylquinazolin-2-amine Chemical compound BrC1=C(C(OC)OC)C=C(OC)C2=NC(NC)=NC=C21 QMRQWRNTAHSJMH-UHFFFAOYSA-N 0.000 description 1
- ZWBJSUIKLFCNTG-UHFFFAOYSA-N 5-bromo-6-(dimethoxymethyl)-8-methoxyquinazolin-2-amine Chemical compound N1=C(N)N=CC2=C(Br)C(C(OC)OC)=CC(OC)=C21 ZWBJSUIKLFCNTG-UHFFFAOYSA-N 0.000 description 1
- KAUUFZXEWMYZPP-UHFFFAOYSA-N 5-bromo-8-methoxy-n,n-dimethylquinazolin-2-amine Chemical compound N1=C(N(C)C)N=C2C(OC)=CC=C(Br)C2=C1 KAUUFZXEWMYZPP-UHFFFAOYSA-N 0.000 description 1
- FIRMESATYUJMPO-UHFFFAOYSA-N 5-bromo-8-methoxyquinazolin-2-amine Chemical compound N1=C(N)N=C2C(OC)=CC=C(Br)C2=C1 FIRMESATYUJMPO-UHFFFAOYSA-N 0.000 description 1
- MNNQIBXLAHVDDL-UHFFFAOYSA-N 5-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)C=N1 MNNQIBXLAHVDDL-UHFFFAOYSA-N 0.000 description 1
- COWZPSUDTMGBAT-UHFFFAOYSA-N 5-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)S1 COWZPSUDTMGBAT-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- QRUAWLFFKOHOFM-UHFFFAOYSA-N 6-[5-(3-chlorophenyl)-8-methoxy-2-(methylamino)quinazolin-7-yl]-3h-1,3-benzoxazol-2-one Chemical compound C=1C(C=2C=C3OC(=O)NC3=CC=2)=C(OC)C2=NC(NC)=NC=C2C=1C1=CC=CC(Cl)=C1 QRUAWLFFKOHOFM-UHFFFAOYSA-N 0.000 description 1
- OCLRVBOCPPDQHJ-UHFFFAOYSA-N 6-bromo-2-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C(C=O)=C1F OCLRVBOCPPDQHJ-UHFFFAOYSA-N 0.000 description 1
- HECJMTPEVWQFCY-UHFFFAOYSA-N 6-bromo-3h-1,3-benzothiazol-2-one Chemical compound BrC1=CC=C2NC(=O)SC2=C1 HECJMTPEVWQFCY-UHFFFAOYSA-N 0.000 description 1
- OSVLUXMNAVVSNU-UHFFFAOYSA-N 7-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-8-methoxy-n-methyl-5-phenylquinazolin-2-amine Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=CC=CC=2)=CC=1C(CC1)=CCC21OCCO2 OSVLUXMNAVVSNU-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- FLCXOSXWPUVOCK-UHFFFAOYSA-N 7-bromo-8-methoxy-n,n-dimethyl-5-(3-nitrophenyl)quinazolin-2-amine Chemical compound C12=CN=C(N(C)C)N=C2C(OC)=C(Br)C=C1C1=CC=CC([N+]([O-])=O)=C1 FLCXOSXWPUVOCK-UHFFFAOYSA-N 0.000 description 1
- HUMLZJNHKMSIOB-UHFFFAOYSA-N 7-bromo-8-methoxy-n-methyl-5-phenylquinazolin-2-amine Chemical compound C=1C(Br)=C(OC)C2=NC(NC)=NC=C2C=1C1=CC=CC=C1 HUMLZJNHKMSIOB-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- VYCGTKRJHDNUNX-UHFFFAOYSA-N 8-methoxy-5-phenylquinazolin-2-amine Chemical compound C12=CN=C(N)N=C2C(OC)=CC=C1C1=CC=CC=C1 VYCGTKRJHDNUNX-UHFFFAOYSA-N 0.000 description 1
- SDQNAPYUVCZYDZ-UHFFFAOYSA-N 8-methoxy-n-methyl-5-morpholin-4-ylquinazolin-2-amine Chemical compound C=1C=C(OC)C2=NC(NC)=NC=C2C=1N1CCOCC1 SDQNAPYUVCZYDZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- LDYSWDMNYLEUCU-QETJVCGBSA-N Atidine Natural products C[C@@]12CCC[C@]3(CN(CCO)C1)[C@@H]2CC(=O)[C@]45CC[C@H](C[C@@H]34)C(=C)[C@H]5O LDYSWDMNYLEUCU-QETJVCGBSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- XQCFATPSDSZGQU-IYBDPMFKSA-N COC=1C2=NC(NC)=NC=C2C(C=2C=CC=CC=2)=CC=1[C@@H]1CC[C@H](O)CC1 Chemical compound COC=1C2=NC(NC)=NC=C2C(C=2C=CC=CC=2)=CC=1[C@@H]1CC[C@H](O)CC1 XQCFATPSDSZGQU-IYBDPMFKSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000004157 Nitrosyl chloride Substances 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- RDXARWSSOJYNLI-UHFFFAOYSA-N [P].[K] Chemical compound [P].[K] RDXARWSSOJYNLI-UHFFFAOYSA-N 0.000 description 1
- SKYGTJFKXUWZMD-UHFFFAOYSA-N ac1l2n4h Chemical compound [Co].[Co] SKYGTJFKXUWZMD-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- LEKJTGQWLAUGQA-UHFFFAOYSA-N acetyl iodide Chemical compound CC(I)=O LEKJTGQWLAUGQA-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- DDNKJFBQMQOIKI-UHFFFAOYSA-N cincreasin Chemical compound BrC1=CC=C2NC(=O)OC2=C1 DDNKJFBQMQOIKI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- FIHDBDMETYBONZ-UHFFFAOYSA-N ethyl 2-[4-[5-(3-chlorophenyl)-2-(dimethylamino)-8-methoxyquinazolin-7-yl]-3,6-dihydro-2h-pyridin-1-yl]acetate Chemical compound C1N(CC(=O)OCC)CCC(C=2C(=C3N=C(N=CC3=C(C=3C=C(Cl)C=CC=3)C=2)N(C)C)OC)=C1 FIHDBDMETYBONZ-UHFFFAOYSA-N 0.000 description 1
- BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
- MHSKRYWXPIMKDI-UHFFFAOYSA-N ethyl 3-[8-methoxy-2-(methylamino)-5-phenylquinazolin-7-yl]-2-methylpropanoate Chemical compound C=12C=NC(NC)=NC2=C(OC)C(CC(C)C(=O)OCC)=CC=1C1=CC=CC=C1 MHSKRYWXPIMKDI-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- OFGGZGXWRWYORO-UHFFFAOYSA-N methanol;tetrachloromethane Chemical compound OC.ClC(Cl)(Cl)Cl OFGGZGXWRWYORO-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- LZKBYJDEWNRVNE-UHFFFAOYSA-N n-[5-bromo-6-(dimethoxymethyl)-8-methoxyquinazolin-2-yl]acetamide Chemical compound N1=C(NC(C)=O)N=CC2=C(Br)C(C(OC)OC)=CC(OC)=C21 LZKBYJDEWNRVNE-UHFFFAOYSA-N 0.000 description 1
- ZOXMORJQWVWNHB-UHFFFAOYSA-N n-methylquinazolin-2-amine Chemical compound C1=CC=CC2=NC(NC)=NC=C21 ZOXMORJQWVWNHB-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 description 1
- 235000019392 nitrosyl chloride Nutrition 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BBNYLDSWVXSNOQ-UHFFFAOYSA-N oxolane-2-carbaldehyde Chemical compound O=CC1CCCO1 BBNYLDSWVXSNOQ-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- IFLXVSWHQQZRQI-UHFFFAOYSA-N pyridine-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=C(C(O)=O)C=N1 IFLXVSWHQQZRQI-UHFFFAOYSA-N 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- FDNAPBUWERUEDA-UHFFFAOYSA-N silicon tetrachloride Chemical compound Cl[Si](Cl)(Cl)Cl FDNAPBUWERUEDA-UHFFFAOYSA-N 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- PFYAMVWLZDZJOQ-UHFFFAOYSA-M sodium;2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)F PFYAMVWLZDZJOQ-UHFFFAOYSA-M 0.000 description 1
- AKVBSROGSVKTID-UHFFFAOYSA-M sodium;ethyl acetate;chloride Chemical compound [Na+].[Cl-].CCOC(C)=O AKVBSROGSVKTID-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a 2-aminoquinazoline derivative having a phosphodiesterase (PDE) -IV inhibitory action and the like.
- PDE phosphodiesterase
- TNFo and other inflammatory site-force-in cells TNFo and other inflammatory site-force-in cells
- IAMs intercellular adhesion molecules
- PDE-IV inhibitors suppress the secretion of inflammatory site forces, such as TNFa and interleukin (IL) -8, by increasing cAMP, and are therefore transmitted by these inflammatory site forces. It is expected that it is possible to prevent the prolonged progress of inflammatory reactions and the like. For example, it has been reported that TNFa reduces the phosphorylation mechanism of insulin receptors in muscle and fat cells and contributes to insulin-resistant diabetes mellitus. Bestigation (Journal of Clinical Investigation), 1994, Vol. 94, ⁇ .1543]. Similarly, TNF o has been implicated in the development of autoimmune diseases such as cancer, multiple sclerosis, and Crohn's disease, suggesting that PDE-IV inhibitors may be effective in these diseases. [Nature Medicine, 1995, Volume 1, p. 211; Ibid., 1995, Volume 1, p. 244] 0
- antihypertensive agents containing a 2-aminoquinazoline derivative see Patent Document 1
- PDE inhibitors see Patent Document 2
- PDE-IV inhibitors see Patent Document 3
- serine Z threonine protein ink Nase regulators see Patent Document 4
- antibacterial agents see Patent Document 5
- neuropeptide ligands see Patent Document 6
- developer compositions see Patent Document 7
- Patent Document 1 JP-A-39-25050
- Patent Document 2 WO 93/07124 pamphlet
- Patent Document 3 WO 98/22460 pamphlet
- Patent Document 4 WO 98/50370 pamphlet
- Patent Document 5 US Pat. No. 6,156,758
- Patent Document 6 WO 03/26667 pamphlet
- Patent Document 7 JP-A-6-324437
- An object of the present invention is to provide a 2-aminoquinazoline derivative having a PDE-IV inhibitory action and the like.
- the present invention relates to the following (1)-(36).
- R 1 and R 2 are the same or different and each represents a hydrogen atom, a substituted or unsubstituted lower alkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aromatic Group or a substituted or unsubstituted alicyclic heterocyclic group
- R 1 and R 2 together with an adjacent nitrogen atom form a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted alicyclic heterocyclic group
- R 3 is a substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted cycloaliphatic Represents a heterocyclic group,
- R 4 and R 5 are the same or different and each represents a hydrogen atom, halogen, hydroxy, carboxy, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cyclo Alkenyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkoxy, substituted or unsubstituted lower alkanol, substituted or unsubstituted aryl, substituted or unsubstituted aromatic heterocyclic group or substituted or unsubstituted aliphatic Represents a cyclic heterocyclic group, but does not simultaneously become a hydrogen atom,
- R 6 represents hydroxy or substituted or unsubstituted lower alkoxy), or a pharmacologically acceptable salt thereof.
- R 3 is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted alicyclic heterocyclic group.
- R 3 is a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted alicyclic heterocyclic group.
- R 5 is substituted or unsubstituted aryl or substituted or unsubstituted aromatic heterocyclic ring
- R 5 is lower alkyl substituted with carboxy, lower alkenyl substituted with carboxy, aryl substituted with carboxy, aromatic heterocyclic group substituted with carboxy or alicyclic heterocyclic substituted with carboxy.
- a medicament comprising the 2-aminoquinazoline derivative or the pharmaceutically acceptable salt thereof according to any one of (1) to (30) as an active ingredient.
- the phosphodiesterase (PDE) -IV inhibitor comprising, as an active ingredient, the 2-aminoquinazoline derivative or the pharmaceutically acceptable salt thereof according to (1) or (30).
- step (30) comprises administering an effective amount of the 2-aminoquinazoline derivative or a pharmaceutically acceptable salt thereof described in any one of (30) to (30).
- the step (30) comprises administering an effective amount of the 2-aminoquinazoline derivative or a pharmaceutically acceptable salt thereof described in any one of (30) to (30).
- 2-aminoquinazoline derivatives having a PDE-IV inhibitory action and the like are provided.
- halogen examples include fluorine, chlorine, bromine, and iodine atoms.
- Examples of the lower alkyl moiety of the lower alkyl and the lower alkoxy include a straight-chain or branched-chain alkyl having 11 to 10 carbon atoms, and more specifically, methyl, ethyl, propyl, Isopropyl, butyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclohexyl, heptyl, octyl, nonyl, decyl and the like.
- cycloalkyl moiety of cycloalkyl and cycloalkoxy for example, carbon Examples include cycloalkyl of Formula 3-10, more specifically, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and the like.
- Examples of the lower alkenyl include a straight-chain or branched-chain alkenyl having 2 to 10 carbon atoms, and more specifically, butyl, aryl, 2-butyral, 3-butur, 4-pentur, 6-otatur, 2,6-octagel, 9-decyl and the like.
- Examples of the cycloalkenyl include cycloalkyls having 3 to 10 carbon atoms, and more specifically, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohepturyl, and cyclootatur. , Cyclononyl, cyclodecyl and the like.
- the aryl and the aryl portion of the aralkyl include, for example, aryl having 6 to 14 carbon atoms, and more specifically, phenyl, naphthyl, indul, anthryl and the like.
- the alkylene portion of the aralkyl has the same meaning as the lower alkyl (ii) except that one hydrogen atom has been removed.
- aromatic heterocyclic group examples include a 5- or 6-membered monocyclic aromatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom; A condensed aromatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom, and a sulfur atom, which is a bicyclic or tricyclic fused 8-membered ring, and more specifically, Pyridyl, pyridonyl, pyrazyl, pyrimidinyl, pyridazyl, quinolyl, isoquinolyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, chel, furyl, furazale , Thiazolyl, oxazolyl,
- Examples of the alicyclic heterocyclic group include a 5- or 6-membered monocyclic alicyclic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom; Membered rings are fused bicyclic or tricyclic and are selected from nitrogen, oxygen and sulfur Examples thereof include alicyclic alicyclic heterocyclic groups containing at least one atom, and more specifically, pyrrolidinyl, pyrrolidonyl, piperidino, piperidyl, piperazinyl, morpholinyl-containing morpholinyl, thiomorpholin-containing thiomorpholinyl, homopiperidi-containing homopiperidyl , Homopiperazinyl, tetrahydropyridyl, tetrahydroquinolyl, tetrahydroisoquinolyl, tetrahydrofural, tetrahydroviral, dihydrobenzofurol and the like.
- Lower alkanols include, for example, linear or branched alkanols having 118 carbon atoms, and more specifically, formyl, acetyl, propionyl, butyryl, isobutylinole, norelinole, Isovaleryl, pivaloyl, hexanoyl, heptanoyl, otatanyl and the like.
- aromatic heterocyclic group formed together with the adjacent nitrogen atom for example, a 5- or 6-membered monocyclic aromatic heterocyclic group containing at least one nitrogen atom (The monocyclic aromatic heterocyclic group may contain another nitrogen atom, an oxygen atom or a sulfur atom), a bicyclic or tricyclic at least one nitrogen atom having a 3- to 8-membered ring fused thereto.
- a condensed aromatic heterocyclic group containing an atom (the condensed aromatic heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom) and the like, and more specifically, Examples include pyrrolyl, imidazolyl, indolyl, indazolyl and the like.
- Examples of the alicyclic heterocyclic group formed together with an adjacent nitrogen atom include a 5- or 6-membered monocyclic alicyclic heterocyclic group containing at least one nitrogen atom (such as A monocyclic alicyclic heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom), a 3- or 8-membered fused bicyclic or tricyclic at least one nitrogen A condensed alicyclic heterocyclic group containing an atom (the condensed alicyclic heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom) and the like; Examples thereof include pyrrolidinyl, pyrrolidonyl, piperidino, piperazinyl, morpholine-containing thiomorpholine-containing homopiperidine-containing homopiperazyl, tetrahydropyridyl, tetrahydroquinolyl, tetrahydroisoquinolyl, and the like.
- halogen hydroxy, amino, nitro, mercapto, sulfo, carboxy, methylenedioxy, carbamoyl, sulfamoyl, sulfamoyl, lower alkenyl, cycloalkenyl, lower alkynyl, lower alkoxycarbol, mono- or di-lower alkyl Halobamoyl, lower alkylsulfiel, lower alkylsulfol, lower alkylthio, aryloxy, aralkyloxy, aroyl, aromatic heterocyclic group, alicyclic heterocyclic group, substituted or unsubstituted cycloalkyl (in the substituted cycloalkyl As the substituents, the same or different, for example, Examples include halogen, hydroxy, carboxy, lower alkyl, lower alkoxy, etc.), substituted or unsubstituted lower alkoxy (substituents in the substituted lower alkoxy
- substituted or unsubstituted lower alkanols the substituents in the substituted lower alkanoyl may be the same or different, for example, the number of substituents is 11
- Substituted or unsubstituted aryls the substituents in the substituted aryls may be the same or different and include, for example, halogens, hydroxy, carboxy, and lower substituents having 13 substitutions).
- substituted or unsubstituted Aralkyl substituted or unsubstituted Aralkyl
- substituted or unsubstituted aralkyl may be the same or different and include, for example, 13-substituted halogen, hydroxy, canoleboxy, lower alkoxy, etc.
- substituted or unsubstituted mono- or di-lower alkylamino substituted or unsubstituted mono- or di-lower alkylamino (the Substituents in the substituted mono- or di-lower alkylamino are the same or different and include, for example, halogens having the number of substitution of 113, hydroxy, carboxy and the like).
- the substituent in the substituted aromatic heterocyclic group formed together with the nitrogen atom may be a substituted or unsubstituted lower alkyl in addition to the above-mentioned substituents (the same or the same as the substituent in the substituted lower alkyl).
- substituents the same or the same as the substituent in the substituted lower alkyl.
- halogens with 1 to 3 substituents hydroxy, carboxy, lower alkoxycarbonyl, aromatic heterocyclic groups, alicyclic And the like.
- the substituted aryl may be dihydrobenzozoxazolyl, dihydrobenzothiazolyl, 2-oxodihydrobenzozoazolyl or 2-oxodihydrobenzozoazolyl.
- the substituent in the substituted cycloalkyl, the substituted cycloalkenyl, the substituted alicyclic heterocyclic group and the substituted alicyclic heterocyclic group formed together with the adjacent nitrogen atom may be oxo.
- the cyclic heterocyclic group and the lower alkanol are the above-mentioned halogen (i), lower alkyl (ii), cycloalkyl (iii), lower alkenyl (iv), cycloalkenyl (V), aryl (vi), Alkylene moiety of aralkyl (vii
- the lower alkyl portion of the lower alkoxycarbol, mono- or di-lower alkylamido-containing mono- or di-lower alkylcarbamoyl, lower alkyl sulfiel, lower alkyl sulfol and lower alkylthio has the same meaning as the above lower alkyl (ii) It is.
- the two lower alkyl moieties in the di-lower alkylamino and the di-lower alkyl moieties rubamoyl may be the same or different.
- Examples of the lower alkynyl include a straight-chain or branched-chain alkyl having 2 to 6 carbon atoms, and more specifically, ethur, propargyl, 3-butul, 3-pentyl, 3-hexyl, 4-methyl-2-pentyl and the like.
- aryl portion of aryloxy, arylalkoxy and arylo is synonymous with aryl (vi).
- the alkylene portion of the aralkyloxy has the same meaning as the above lower alkyl (ii) obtained by removing one hydrogen atom.
- Examples of the pharmacologically acceptable salt of compound (I) include pharmacologically acceptable metal salts, ammonium salts, organic amine addition salts, amino acid addition salts, acid addition salts and the like.
- the pharmacologically acceptable metal salts include, for example, alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Lead salts and the like; pharmacologically acceptable ammonium salts include, for example, salts of ammonium and tetramethylammonium; and pharmacologically acceptable organic amines.
- addition salts include addition salts such as morpholine and piperidine, and examples of the pharmacologically acceptable amino acid addition salts include addition salts such as lysine, glycine, and phenylalanine.
- addition salts which are acceptable are, for example, hydrochloride, sulfate
- organic acid salts such as acetate, maleate, fumarate, tartrate, citrate and the like.
- Some compounds (I) may have various stereoisomers, positional isomers, geometric isomers, tautomers and the like.
- the present invention includes all of these possible isomers and mixtures thereof, and the mixing ratio is also arbitrary.
- Compound (I) can be obtained, for example, according to the reaction steps described in Production Method 117 below.
- Me, Et, and Bu in the following production methods and tables represent methyl, ethyl, and butyl, respectively.
- R 4 is a hydrogen atom
- R 5 is R 5a (where R 5a is a substituted or unsubstituted lower alkenyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group)
- R 5a is a substituted or unsubstituted lower alkenyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group
- a compound represented by a cyclic group or a substituted or unsubstituted alicyclic heterocyclic group) can be obtained, for example, by the following Production Method 1. [0032] [Formula 2]
- R 2 , R 3 , R 5a and R 6 are as defined above, and R 5b represents a substituted or unsubstituted alicyclic heterocyclic group.
- Compound (III) can be obtained by reacting compound (II) with 120 equivalents of ⁇ , ⁇ -dimethylformamide (DMF) in a solvent in the presence of 115 equivalents of a base.
- DMF ⁇ , ⁇ -dimethylformamide
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S tetrahydrofuran (THF), getyl ether, 1,4-dioxane, dimethoxyethane and the like can be used.
- THF tetrahydrofuran
- getyl ether 1,4-dioxane, dimethoxyethane and the like
- THF can be used.
- lithium diisopropylamide LDA
- lithium (bistrimethylsilyl) amide As the base, lithium diisopropylamide (LDA), lithium (bistrimethylsilyl) amide and the like can be used, and preferably LDA can be used.
- the reaction is completed at a temperature between ⁇ 78-0 ° C., preferably at ⁇ 78 ° C., with a 5-minute power of about 48 hours.
- Compound (II) can be obtained from a commercially available product or from 4-bromo-2-fluorophenol (commercially available) by a known method for alkylating hydroxy [for example, Protective Groups in Organic'Synthesis. Groups in Organic Synthesis 3 edition, written by TW Greene, John Wiley & Sons Inc., 145 (1999)] It can be obtained by an equivalent method.
- This step is performed by a known method [for example, see Journal of Heterocyclic Chemistry, vol. 34, p. 385 (1997)] or a method similar thereto. Can be done in any way.
- Compound (V) can be obtained by reacting compound (III) with 120 equivalents of compound (IV) in a solvent in the presence of 120 equivalents of a base.
- the solvent is not particularly limited as long as it is inert to the reaction.
- ⁇ ⁇ ⁇ -dimethylacetoamide
- DMF dimethyl sulfoxide
- DMSO dimethyl sulfoxide
- DMA can be used.
- potassium carbonate for example, potassium carbonate, cesium carbonate, sodium methoxide, potassium tert-butoxide and the like can be used, and preferably, potassium carbonate or cesium carbonate is used.
- the reaction is completed at a temperature between room temperature and 180 ° C, preferably at 160 ° C, in about 5 minutes to 48 hours.
- Compound (IV) can be obtained as a commercial product or by a known method [for example, see Journal of Organic Chemistry, vol. 57, p. 2497 (1992)] or It can be obtained by a similar method.
- Compound (VIII) is obtained by reacting compound (V) with 112 equivalents of compound (VI) or (VII) in a solvent in the presence of 0.1-10 equivalents of a base and 0.001-1 equivalents of a palladium catalyst. be able to.
- the solvent is not particularly limited as long as it is inert to the reaction.
- Examples of the base include pyridine, triethylamine, ⁇ -methylmorpholine, ⁇ -methylbiperidine, piperidine, piperazine, potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, Lithium hydroxide, potassium hydroxide, phosphoric acid And sodium tert-butoxide, 1,8-diazabicyclo [5.4.0] -7-pandecene (DBU), diisopropylethylamine and the like, and preferably sodium carbonate.
- a base may not be used.
- Examples of the palladium catalyst include palladium sources such as palladium acetate, palladium trifluoroacetate, tris (dibenzylideneacetone) dipalladium, and carohydrates thereof with a chromate form.
- Examples of the ligand include palladium.
- Triphenylphosphine ⁇ , -bis (diphenylphosphino) phenene, 0-tolylphosphine, 1,2-bis (diphenylphosphino) ethane, 1,3- (bisdiphenylphosphino) propane, 1,4- Bis (diphenylphosphino) butane, di-tert-butyldiphenylphosphine, 2- (di-tert-butylphosphino) biphenyl, 2- (dicyclohexylphosphino) biphenyl and the like can be used. It is preferable to use 110 equivalents to palladium.
- ligands suitable for carrying out the reaction such as tetrakis (triphenylphosphine) palladium, 1,1'-bis (diphenylphosphino) phenethyl sendichloropalladium ⁇ dichloromethane 1: 1 adduct, are prepared in advance. It is better to use a sales reagent coordinated with palladium.
- reaction is completed at a temperature between room temperature and the boiling point of the solvent used, preferably at 100 ° C, with a 5 minute power of about 48 hours.
- Compound (VI) and compound (VII) can be obtained as a commercial product or by a known method [for example, see Shin-Jikken Kagaku Koza, Vol. 12, Nippon Dani Gakkai (1978), etc.] or a method analogous thereto. .
- Compound (la) can be obtained by reacting compound (VIII) with 120 equivalents of bromine in a solvent.
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S For example, acetic acid, carbon tetrachloride, chloroform, dichloromethane, 1,2-dichloroethane, dioxane, THF And ethyl acetate can be used, and acetic acid can be preferably used.
- the reaction is completed at a temperature between 0 ° C. and the boiling point of the solvent used, preferably at 60 ° C., for about 48 hours with a 5 minute force.
- bromine for example, N-bromosuccinimide, pyrrolidone tripromide, cuprous bromide or pyridi-dimethyltribamide may be used, and the reaction may be carried out using a reaction solvent suitable for each reagent. it can.
- the solvent is not particularly limited as long as it is inert to the reaction, but is not particularly limited, for example, acetonitrile, methanol, ethanol, dichloromethane, 1,2-dichloroethane, chlorophonolem, dimethoxyethane, DMF, dioxane , THF, dimethyl ether, diisopropyl ether, N, N-dimethylimidazolidinone, N-methylpyrrolidone, sulfolane, and the like, and preferably DMF.
- Compound (lb) is prepared by using compound (la) and compound (IX) or compound (X) and performing the same reaction as in step 3, or converting compound (la) into compound (XI) under the same conditions. ).
- Compound (IX) and compound (X) can be obtained as commercial products or by a known method [for example, see New Experimental Chemistry Course, Vol. 12, Nippon Dani Gakkai (1978), etc.] or a method analogous thereto. be able to.
- Compound (lb) can also be obtained, for example, by the following production method 2.
- X 1 represents a leaving group usually used in organic synthetic chemistry such as a chlorine atom, a bromine atom, an iodine atom, methanesulfonyloxy, and trifluoromethanesulfo-loxy; R 5a and R 6 are the same as defined above.
- Compound (XII) can be obtained by performing the same reaction as in Step 3 of Production Method 1 using compound (la) and bis (pinacolato) diboron (commercially available).
- Compound (XIII) can be obtained as a commercial product or by a known method (for example, see Shin-Jikken Kagaku Koza, Vol. 14, Chemical Society of Japan (1978)) or a method analogous thereto. Manufacturing method 3
- R 6 are as defined above, and R ′ represents a substituted or unsubstituted lower alkyl.
- Compound (Ic) can be obtained by reacting compound (la) with 120 equivalents of compound (XIV) in a solvent in the presence of 0.1-10 equivalents of a base and 0.001-1 equivalents of a palladium catalyst. it can.
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S For example, acetonitrile, 1,2-dichloroethane, DMA, DMF, DMSO, dioxane, THF, benzene, toluene, xylene , ⁇ , ⁇ -dimethylimidazolidinone, ⁇ -methylpyrrolidone, sulfolane and the like can be used, and preferably DMF can be used.
- Bases include triethylamine, pyridine, ⁇ -methylmorpholine, ⁇ -methylbiperidine, piperidine, piperazine, potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, lithium hydroxide , Potassium hydroxide, phosphoric acid And sodium tert-butoxide, DBU, diisopropylethylamine and the like, and preferably triethylamine.
- Examples of the palladium catalyst include palladium sources such as palladium acetate, palladium trifluoroacetate, tris (dibenzylideneacetone) dipalladium, and carohydrate with a chromate form thereof.
- Examples of the ligand include palladium.
- Triphenylphosphine ⁇ , -bis (diphenylphosphino) phenene, 0-tolylphosphine, 1,2-bis (diphenylphosphino) ethane, 1,3- (bisdiphenylphosphino) propane, 1,4- Bis (diphenylphosphino) butane, di-tert-butyldiphenylphosphine, 2- (di-tert-butylphosphino) biphenyl, 2- (dicyclohexylphosphino) biphenyl and the like can be used. It is preferable to use 110 equivalents to palladium.
- ligands suitable for carrying out the reaction such as tetrakis (triphenylphosphine) palladium, 1,1'-bis (diphenylphosphino) phenethyl sendichloropalladium ⁇ dichloromethane 1: 1 adduct, are prepared in advance. It is better to use a sales reagent coordinated with palladium.
- reaction is completed at a temperature between room temperature and the boiling point of the solvent used, preferably at 100 ° C, for about 48 hours with a 5 minute power.
- Compound (XIV) can be obtained as a commercially available product, or by a known method [see, for example, New Experimental Chemistry Course, Vol. 12, Chemical Society of Japan (1978)] or a method analogous thereto.
- Process 2
- Compound (Id) can be obtained by reacting compound (Ic) without solvent or in a solvent with 11-200 equivalents of a base or a catalytic amount of 200 equivalents of an acid.
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S For example, methanol, ethanol, 1-propanol, acetone, methyl ethyl ketone, dimethyl ether, THF, dioxane, DMF, dichloromethane, 1,2-dichloroethane, etc.
- a mixed solution or the like mixed at an appropriate ratio of up to 100 can be used, and a 1: 4 mixed solution of water and methanol is preferably used.
- sodium hydroxide, potassium hydroxide, lithium hydroxide and the like can be used, and preferably lithium hydroxide can be used.
- acid hydrochloric acid, sulfuric acid, acetic acid, formic acid, trifluoroacetic acid, P-toluenesulfonic acid, methanesulfonic acid, titanium tetrachloride, boron trifluoride, or the like can be used, and preferably trifluoroacetic acid can be used. .
- the reaction is completed at a temperature between 0 ° C. and the boiling point of the solvent used, preferably at room temperature, for about 5 minutes to 48 hours.
- Compound (Ie) can be obtained by subjecting compound (Ic) to a catalytic reduction reaction.
- the solvent is not particularly limited as long as it is inert to the reaction.
- a mixed solution or the like mixed at an appropriate ratio of 1 to 1 to 100 can be used, and preferably ethanol can be used.
- the conditions for the catalytic reduction reaction are as follows: under the presence of a catalyst usually used in catalytic reduction reactions such as palladium carbon, platinum dioxide, Raney nickel, etc., under a hydrogen pressure of from normal pressure to 50,000 kPa, or 1 200 equivalents of ammonia, acetic acid, hydrochloric acid, sulfuric acid, etc., if necessary, in the presence of 200 equivalents of hydrogen donors such as formic acid, ammonium formate, hydrazine, cyclohexene, cyclohexene, and triethylsilane.
- the conditions under which the addition is performed can be raised, and preferably the conditions can be used in the presence of 10% by weight of palladium carbon under normal hydrogen pressure.
- reaction is completed in about 5 minutes to 48 hours at a temperature between 0 ° C and the boiling point of the solvent used, preferably at room temperature.
- Compound (Ie) can also be obtained by reacting compound (Ic) with 1,200 equivalents of a reducing agent in a solvent.
- the solvent is not particularly limited as long as it is inert to the reaction.1S
- methanol, ethanol, acetic acid, ethyl acetate, THF, dioxane and the like can be used, and methanol is preferably used. it can.
- sodium borohydride sodium hydride / silicon chloride, sodium hydride / cobalt cobalt, sodium cyanoborohydride, or the like can be used.
- Sodium can be used.
- the reaction is completed in about 5 minutes to 48 hours at a temperature between 0 ° C. and the boiling point of the solvent used, preferably at room temperature.
- Compound (If) can be obtained by performing the same reaction as in Step 2 of Production Method 3 using Compound (Ie).
- Compound (VIII) can also be obtained, for example, by the following production method 4.
- Compound (XV) can be obtained by performing the same reaction as in Step 3 of Production Method 1 using Compound (V) and bis (pinacolato) diboron (commercially available).
- Compound (VIII) can be obtained by performing the same reaction as in Step 3 of Production Method 1 using Compound (XV) and Compound (XVI).
- Compound (XVI) can be obtained as a commercial product, or by a known method [see, for example, New Experimental Chemistry Lecture, Vol. 14, The Chemical Society of Japan (1978)] or a method analogous thereto. Manufacturing method 5
- the compound (Ih) is obtained by converting the compound (Ig) into the conditions for demethylidation reaction of arylmethyl ether commonly used in organic synthetic chemistry [for example, Protective Groups in Organic Synthesis]. Organic Synthesis 3 Edition), written by TW Greene, John Wiley & Sons, Inc. (John Wiley & Sons, Inc.), page 249 (1999), etc. Or an equivalent method].
- Compound (Ig) can be obtained by the method described in Production Method 13 or a method analogous thereto.
- Compound (Ii) can be obtained by reacting compound (Ih) with 120 equivalents of compound (XVII) in a solvent in the presence of 120 equivalents of a base.
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S dimethoxyethane, DMF, dioxane, THF, detinoleate ether, diisopropyl ether, benzene, toluene , Xylene, pyridine, ⁇ , ⁇ -dimethylimidazolidinone, ⁇ -methylpyrrolidone, sulfolane, etc., and preferably THF or DMF can be used.
- Examples of the base include sodium hydride, potassium tert-butoxide, potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, phosphoric acid, and the like. Potassium or the like can be used, and preferably, sodium hydride can be used.
- Compound (XVII) can be obtained as a commercial product or by a known method [for example, see Shin-Jikken Kagaku Koza, Vol. 14, Chemical Society of Japan (1978)] or a method analogous thereto. Manufacturing method 6
- Compound (I) can be obtained, for example, by the following production method 6.
- L represents a leaving group such as a chlorine atom, a bromine atom, and an iodine atom
- R 3 , R 5 and R 8 are as defined above.
- Compound (Ik) is obtained by reacting compound (Ij) in the absence of a solvent or in a solvent, if necessary, in the presence of 1.1-1000 equivalents of an acid and 1.1-1000 equivalents of a halogen source; Can be obtained from the reaction.
- the solvent is not particularly limited as long as it is inert to the reaction.
- THF trifluoroethyl ether
- dioxane acetone
- DMSO dimethyl sulfoxide
- DMF dimethyl sulfoxide
- water a mixed solvent thereof or the like is used.
- V and preferably THF or water can be used.
- hydroiodic acid hydrobromic acid, hydrochloric acid and the like can be used.
- the sources of copper and copper are copper chloride (I), copper bromide (I), copper iodide (I), copper chloride ( ⁇ ), and copper bromide ( ⁇ ).
- Copper iodide (11), potassium iodide, iodine methane and the like can be used, and preferably, copper iodide (I) or iodine methane can be used.
- nitrite compound nitrites such as nitrite and sodium nitrite; halogenated trosyls such as nitrosyl chloride; tert-butyl nitrite; and alkyl nitrites such as isoamyl nitrite can be used.
- nitrites such as nitrite and sodium nitrite
- halogenated trosyls such as nitrosyl chloride
- tert-butyl nitrite tert-butyl nitrite
- alkyl nitrites such as isoamyl nitrite
- sodium nitrite or isoamyl nitrite is used.
- the reaction is completed at a temperature between -30 ° C and the boiling point of the solvent used, preferably at 60 ° C in about 5 minutes to 48 hours.
- Compound (Ij) can be obtained by the method described in Production Method 13 or 5 or a method analogous thereto.
- Process 2
- Compound (I) can be obtained by reacting compound (Ik) with 1-1000 equivalents of amine (XVIII) in the absence of a solvent or in a solvent, if necessary, in the presence of 1-100 equivalents of a base group. .
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S For example, acetonitrile, methanol, ethanol, dichloromethane, chloroform, THF, dioxane, acetone, DMSO, DMF, etc.
- DMF or THF can be used.
- pyridine triethylamine, diisopropylethylamine, N-methylmorpholine, DBU and the like can be used, and preferably triethylamine can be used.
- the reaction is completed in a temperature between room temperature and the boiling point of the solvent used, preferably at room temperature for about 5 minutes to 48 hours.
- Compound (XVIII) is commercially available.
- Compound (I) can be obtained, for example, by the following production method 7.
- R 4 , R 5 , R 8 and X 1 are as defined above.
- Compound (XIX) can be obtained by reacting compound (Ij) with no solvent or in a solvent, if necessary, in the presence of 11-1000 equivalents of a base, and 1-1000 equivalents of an acetylethylamine reagent. it can.
- the solvent is not particularly limited as long as it is inert to the reaction.
- acetonitrile, dichloromethane, chloroform, THF, dioxane, acetone, DMSO, DMF and the like can be used.
- dichloromethane can be used.
- the base for example, pyridine, triethylamine, diisopropylethylamine, N-methylmorpholine, DBU and the like can be used, and preferably, pyridine and triethylamine can be used.
- a base such as pyridine can also be used as a solvent.
- acetyldiazole reagent examples include, for example, chloroacetic acid acetyl, acetic anhydride and the like.
- the reaction is completed at a temperature between 0 ° C. and the boiling point of the solvent used, preferably at 80 ° C. in about 5 minutes to 48 hours.
- Compound (XXI) can be obtained by reacting compound (XIX) with 120 equivalents of compound (XX) in the presence of 120 equivalents of a base in a solvent.
- the solvent is not particularly limited as long as it is inert to the reaction.
- 1S dimethoxyethane, DMF, dioxane, THF, detinoleate ether, diisopropyl ether, benzene, toluene , Xylene, pyridine, ⁇ , ⁇ -dimethylimidazolidinone, ⁇ -methylpyrrolidone, sulfolane, etc., and preferably THF or DMF can be used.
- Examples of the base include, for example, sodium hydride, potassium tert-butoxide, potassium acetate, potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, phosphorus Potassium acid or the like can be used, and preferably, sodium hydride can be used.
- Compound (XX) is commercially available.
- Compound (I) can be obtained by reacting compound (XXI) with 1,200 equivalents of a base in a solvent.
- the solvent is not particularly limited as long as it is inert to the reaction. i
- a mixed solution or the like mixed at an appropriate ratio of up to 1: 100 can be used, and preferably, methanol can be used.
- potassium carbonate cesium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like, preferably potassium carbonate can be used.
- the reaction is completed in about 5 minutes to 48 hours at a temperature between 0 ° C. and the boiling point of the solvent used, preferably at room temperature.
- the intermediates and target compounds in each of the above production methods are isolated and purified by separation and purification methods commonly used in synthetic organic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, and various types of chromatography. be able to. Further, the intermediate can be subjected to the next reaction without purification.
- compound (I) When the salt of compound (I) is obtained, if compound (I) is obtained in the form of a salt, it may be purified as it is, or if compound (I) is obtained in the free form, compound (I) May be dissolved or suspended in an appropriate solvent, and an acid or a base may be added thereto for isolation and purification.
- Compound (I) and its pharmacologically acceptable salts may be present in the form of a carohydrate with water or various solvents. These adducts are also included in the present invention.
- Test example Recombinant human PDE-IV inhibition test
- HSPDE4A Human PDE cDNA
- HSPDE4A4A4 Human PDE cDNA
- S19 insect cells PDE activity was measured by the following two-step process according to the method of Kincid RL and Manganiello VC [Method. Enzymol., 1988, Vol. 159, p.457].
- [ 3 H] cAMP (final concentration: 1 ⁇ mol / L) was used as the substrate, and the reaction was performed using ⁇ , ⁇ -bis (2-hydroxyethyl) -2-aminoethanesulfonate (50 mmol / L, pH 7.2), a standard mixture containing magnesium chloride (1 mmol / L) and Soybean trypsin inhibitor (0.1 mg / mL). The reaction was started by adding enzyme and incubated at 30 ° C for 10-30 minutes. The reaction was stopped with hydrochloric acid, and the generated 5, -AMP was completely decomposed by 5'-nucleotidase. Eluted [ 3 H] adenosine was counted with a scintillation counter after treatment by mouth chromatography with DEAE-Sephadex A-25. The drug was added dissolved in DMSO (concentration 1.7%).
- Compound (I) or a pharmacologically acceptable salt thereof can be administered alone as it is, but it is usually desirable to provide it as various pharmaceutical preparations.
- the pharmaceutical preparations are used for animals and humans.
- the pharmaceutical preparation according to the present invention comprises compound (I) or a pharmaceutically acceptable salt thereof alone, as an active ingredient, in combination with any other active ingredient for treatment. It can be contained as a mixture.
- these pharmaceutical preparations are prepared by mixing the active ingredient with one or more pharmacologically acceptable carriers and by any method well known in the technical field of pharmaceutics.
- Examples of the administration route include oral administration where it is desirable to use the most effective one for treatment, and parenteral administration such as intravenous administration.
- Examples of the administration form include tablets, injections and the like.
- Tablets and the like suitable for oral administration include excipients such as lactose and mannitol; disintegrants such as starch; lubricants such as magnesium stearate; binders such as hydroxypropylcellulose.
- a surfactant such as a fatty acid ester, a plasticizer such as glycerin, and a preservative such as benzoic acid and P-hydroxybenzoic acid esters.
- a sterile aqueous preparation containing an active conjugate which is preferably isotonic with the blood of the recipient, for example, a salt solution, a glucose solution or A solution for injection is prepared using a carrier composed of a mixture of saline and glucose solution.
- the dose and frequency of compound (I) or a pharmaceutically acceptable salt thereof will vary depending on the dosage form, the age and weight of the patient, the nature or severity of the condition to be treated, and the like.
- oral administration administer 0.01 mg to 1 g, preferably 0.05 to 50 mg per adult, once or several times a day.
- parenteral administration such as intravenous administration
- 0.001 to 100 mg, preferably 0.01 to 50 mg, per adult is administered once or several times a day.
- the dose and the number of administrations vary depending on the various conditions described above.
- a compound c was synthesized in the same manner as in Reference Example 2 using Compound a and 1,1-dimethyldiazine sulfate.
- Reference Example 14 The same as in Reference Example 6 using 5- (3-chlorophenyl) -8-methoxy-2- (methylamino) quinazoline (di-n-conjugated n) compound e and 3-chlorophenylboronic acid. Compound n was synthesized by the method.
- Example 6 Compound 6 was synthesized in the same manner as in Example 1 using 7-bromo-5- (3-cyanophenol) -2-dimethylamino-8-methoxyquinazoline (disulfide compound 6). .
- Compound 22 was synthesized in the same manner as in Example 21 using Compound 3 as in Example V.
- Compound 21 was synthesized in the same manner as in Example 27 using Compound 21.
- Compound 25 was synthesized using Compound V in the same manner as in Example 27 to prepare Compound 31.
- Step 1 The compound obtained in Step 1 (280 mg, 0.791 mmol) was dissolved in THF (15 mL) and water (3 mL), and a 2.5% aqueous osmium tetroxide solution (0.16 mL, 0.016 mmol) and 50% methyl morpholine were dissolved. An aqueous solution of -N-oxide (0.185 mL, 0.791 mmol) was added, and the mixture was stirred at room temperature for 24 hours. The organic layer of the reaction mixture was extracted with water and black-mouthed form, washed with saturated saline, and dried over anhydrous magnesium sulfate.
- Compound 37 was synthesized in the same manner as in Example 11 using Compound 5 and 3-carboxyphenylboronic acid.
- Compound 38 was synthesized in the same manner as in Example 11 using Compound 7 and 3-carboxyphenylboronic acid.
- Compound 46 was synthesized in the same manner as in Example 11 using compound bf and methyl 3-methoxy-4-trifluoromethanesulfo-hydroxybenzoate (for example, it can be obtained by the method described in WO2003 / 048137). did.
- Compound 47 was synthesized in the same manner as in Example 11 using compound bf and 4-bromo-3-hydroxybenzoic acid (for example, obtainable by the method described in W099 / 16747).
- Compound 48 was synthesized in the same manner as in Example 11, using compound bf and methyl 3-chloro-4-trifluoromethanesulfo-loxybenzoate (obtainable, for example, by the method described in WO2002 / 022113). did.
- Example 11 was carried out using 5- (3-chlorophenol) -8-methoxy-2-methylamino-7-phenylquinazoline (di-conjugated compound 51) compound 8 and phenolic boric acid.
- Compound 51 was synthesized in a similar manner. JH NMR (CDC1, ⁇ ): 3.17 (brs, 3 ⁇ ), 4.07 (s, 3 ⁇ ), 5.38 (brs, 1H), 6.99-7.28 (m,
- Compound 72 was synthesized in the same manner as in Example 11 using compound bf and 5- (4-bromophenyl) -1H-tetrazole.
- 5-bromofuran-2-ylacetic acid ethyl ester obtained in step 1 5-bromofuran-2-ylacetic acid was synthesized in the same manner as in Example 27.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002560098A CA2560098A1 (en) | 2004-03-15 | 2005-03-15 | 2-aminoquinazoline derivative |
US10/592,955 US20070225308A1 (en) | 2004-03-15 | 2005-03-15 | 2-Amino Quinazoline Derivative |
JP2006511041A JPWO2005087749A1 (ja) | 2004-03-15 | 2005-03-15 | 2−アミノキナゾリン誘導体 |
EP05720820A EP1726584A4 (en) | 2004-03-15 | 2005-03-15 | 2-AMINOCHINAZOLINDERIVAT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004073322 | 2004-03-15 | ||
JP2004-073322 | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005087749A1 true WO2005087749A1 (ja) | 2005-09-22 |
Family
ID=34975509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004565 WO2005087749A1 (ja) | 2004-03-15 | 2005-03-15 | 2−アミノキナゾリン誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070225308A1 (ja) |
EP (1) | EP1726584A4 (ja) |
JP (1) | JPWO2005087749A1 (ja) |
CA (1) | CA2560098A1 (ja) |
WO (1) | WO2005087749A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118256A1 (ja) * | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
WO2008052734A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2010035745A1 (ja) | 2008-09-25 | 2010-04-01 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするpde阻害剤 |
WO2010041711A1 (ja) | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするpde阻害剤 |
EP2286813A2 (en) | 2006-01-31 | 2011-02-23 | Novartis AG | Use of naphthyridine derivatives as medicaments |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
JP2015057410A (ja) * | 2009-09-03 | 2015-03-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カリウムイオンチャネルインヒビターとしてのキナゾリン |
JP2019527718A (ja) * | 2016-08-08 | 2019-10-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tlr7/8アンタゴニストおよびそれらの使用 |
US11629134B2 (en) | 2015-12-17 | 2023-04-18 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100134693A (ko) * | 2008-04-23 | 2010-12-23 | 교와 핫꼬 기린 가부시키가이샤 | 2-아미노퀴나졸린 유도체 |
WO2009155121A2 (en) * | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5692875A (en) * | 1979-12-27 | 1981-07-27 | Dainippon Pharmaceut Co Ltd | 2-aminoquinazoline derivative |
JPH08501538A (ja) * | 1992-09-14 | 1996-02-20 | シエーリング アクチエンゲゼルシヤフト | ホスホジェステラーゼ ▲iv▼のインヒビターの新規使用 |
WO1998022460A1 (en) * | 1996-11-15 | 1998-05-28 | Darwin Discovery Limited | Bicyclic aryl carboxamides and their therapeutic use |
US6153758A (en) * | 1996-11-20 | 2000-11-28 | Chemi S.P.A. | Heteroarylic-arylic diphosphines as chiral ligands |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
JP2005154434A (ja) * | 2003-11-05 | 2005-06-16 | Kyowa Hakko Kogyo Co Ltd | 2−アミノキナゾリン誘導体 |
-
2005
- 2005-03-15 EP EP05720820A patent/EP1726584A4/en not_active Withdrawn
- 2005-03-15 US US10/592,955 patent/US20070225308A1/en not_active Abandoned
- 2005-03-15 CA CA002560098A patent/CA2560098A1/en not_active Abandoned
- 2005-03-15 WO PCT/JP2005/004565 patent/WO2005087749A1/ja active Application Filing
- 2005-03-15 JP JP2006511041A patent/JPWO2005087749A1/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5692875A (en) * | 1979-12-27 | 1981-07-27 | Dainippon Pharmaceut Co Ltd | 2-aminoquinazoline derivative |
JPH08501538A (ja) * | 1992-09-14 | 1996-02-20 | シエーリング アクチエンゲゼルシヤフト | ホスホジェステラーゼ ▲iv▼のインヒビターの新規使用 |
WO1998022460A1 (en) * | 1996-11-15 | 1998-05-28 | Darwin Discovery Limited | Bicyclic aryl carboxamides and their therapeutic use |
US6153758A (en) * | 1996-11-20 | 2000-11-28 | Chemi S.P.A. | Heteroarylic-arylic diphosphines as chiral ligands |
Non-Patent Citations (2)
Title |
---|
LI J.S. ET AL: "Design of Triple Helix Forming C-Glycoside Molecules.", JOURNAL OF AMERICAN CHEMICAL SOCIETY., vol. 125, no. 8, 2003, pages 2084 - 2093, XP002989835 * |
See also references of EP1726584A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118256A1 (ja) * | 2005-04-28 | 2006-11-09 | Kyowa Hakko Kogyo Co., Ltd. | 2-アミノキナゾリン誘導体 |
US7906522B2 (en) | 2005-04-28 | 2011-03-15 | Kyowa Hakko Kirin Co., Ltd | 2-aminoquinazoline derivatives |
EP2286813A2 (en) | 2006-01-31 | 2011-02-23 | Novartis AG | Use of naphthyridine derivatives as medicaments |
WO2008052734A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
WO2010035745A1 (ja) | 2008-09-25 | 2010-04-01 | 杏林製薬株式会社 | ヘテロ環ビアリール誘導体及びそれらを有効成分とするpde阻害剤 |
WO2010041711A1 (ja) | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするpde阻害剤 |
JP2015057410A (ja) * | 2009-09-03 | 2015-03-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カリウムイオンチャネルインヒビターとしてのキナゾリン |
US9458114B2 (en) | 2009-09-03 | 2016-10-04 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
US9822096B2 (en) | 2009-09-03 | 2017-11-21 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
US10214511B2 (en) | 2009-09-03 | 2019-02-26 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
US10676460B2 (en) | 2009-09-03 | 2020-06-09 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
US11008306B2 (en) | 2009-09-03 | 2021-05-18 | Bristol-Myers Squibb Company | Quinazolines as potassium ion channel inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012034091A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Imidazo [1, 2] pyridazin compounds and compositions as trk inhibitors |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
US11629134B2 (en) | 2015-12-17 | 2023-04-18 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
JP2019527718A (ja) * | 2016-08-08 | 2019-10-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tlr7/8アンタゴニストおよびそれらの使用 |
JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tlr7/8アンタゴニストおよびそれらの使用 |
US11512069B2 (en) | 2016-08-08 | 2022-11-29 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1726584A4 (en) | 2009-05-13 |
JPWO2005087749A1 (ja) | 2007-08-09 |
US20070225308A1 (en) | 2007-09-27 |
CA2560098A1 (en) | 2005-09-22 |
EP1726584A1 (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005087749A1 (ja) | 2−アミノキナゾリン誘導体 | |
US11672799B2 (en) | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | |
AU2016256728B2 (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions | |
EP3564233B1 (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
EP3040331B1 (en) | Tetrahydrocyclopentapyrrole derivative and preparation method therefor | |
JP5242391B2 (ja) | Tgf−ベータ阻害剤としてのピリジンキノリン置換ピロロ[1,2−b]ピラゾール一水和物 | |
ES2674813T3 (es) | Compuesto heterocíclico que contiene nitrógeno parcialmente saturado | |
WO2006129623A1 (ja) | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 | |
WO2006080450A1 (ja) | Igf-1r阻害剤 | |
AU2014228206A1 (en) | Substituted xanthines and methods of use thereof | |
WO2001027105A1 (fr) | Composes de pyrimidine-5-carboxamide, procede de preparation et d'utilisation desdits composes | |
WO2006008874A1 (ja) | アミノチアゾール骨格を有するCdk4,6選択的阻害剤 | |
EP3227270A2 (en) | Heterocyclic derivatives and use thereof | |
EP4212524A1 (en) | Cd73 inhibitor and application thereof in medicine | |
WO2006137421A1 (ja) | 局所投与剤 | |
WO2011014888A1 (en) | Novel hedgehog inhibitors | |
WO2019136093A1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof | |
CN112142757B (zh) | 五元含氮杂芳基取代的嘧啶二酮类化合物及其用途 | |
CN110437235B (zh) | 3-酰胺氮杂吲哚类化合物作为肥大细胞调节剂及其制备方法和用途 | |
JP2023547306A (ja) | アリールアミド化合物、それを含む医薬組成物、その製造方法及びそれらの使用 | |
CN116438181A (zh) | 磺酰胺基取代的杂芳基嘧啶二酮类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511041 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2560098 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005720820 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10592955 Country of ref document: US Ref document number: 2007225308 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005720820 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10592955 Country of ref document: US |